HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Mladen J. Kocica Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kocica, M. J. Search for Related Content PubMed Articles by Kocica, M. J. Related Collections Cardiac - other

Ann Thorac Surg 2004;77:2011
© 2004 The Society of Thoracic Surgeons

Invited commentary

UC Clinical Centre of Serbia, Institute for Cardiovascular Diseases, Clinic for Cardiac Surgery, 8th Kosta Todorovic St 11000 Belgrade, Serbia and Montenegro, Slovak Republic

e-mail: kocica@sezampro.yu

The first 20% of the full text of this article appears below.

In their paper, Friehs and colleagues show that performance of hypertrophied myocardium can be preserved by inducing therapeutic angiogenesis, with a single dose of VEGF-165, given into the pericardial sac. Their previous results have demonstrated numerous deleterious effects that accompany the concentric hypertrophic response of the rabbit heart, exposed to pressure overload.

In this study, 10-day-old rabbits, divided into two experimental groups (VEGF treated and untreated) were exposed to pressure overload for 4 weeks. The control group consisted of age-matched, nonhypertrophied, untreated animals. Progression and extent of myocardial hypertrophy (LV mass to volume and LV to body weight ratio), and in-vivo . . . [Full Text of this Article]